documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
45 rows where docket_id = "FDA-2026-P-6737" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, open_for_comment, posted_date (date), comment_start_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2026-P-6737-0009 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 7 - Incorporation of excess gadolinium into human bone from medical contrast agents | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:46Z | 0 | 0 | 09000064b932a303 | |||
| FDA-2026-P-6737-0012 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 10 - Gadolinium-Based Contrast Agent Accumulation and Toxicity | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:55Z | 0 | 0 | 09000064b932a306 | |||
| FDA-2026-P-6737-0003 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 1 - Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:26Z | 0 | 0 | 09000064b932a273 | |||
| FDA-2026-P-6737-0008 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 6 - Literature case analysis of nephrogenic systemic fibrosis induced by gadolinium-based contrast agents | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:43Z | 0 | 0 | 09000064b932a302 | |||
| FDA-2026-P-6737-0043 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 41 - Long-Term Treatment with Gadopentetic Acid or Gadodiamide | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:44Z | 0 | 0 | 09000064b932a33d | |||
| FDA-2026-P-6737-0040 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 38 - Ultrastructural Evidence of Dermal Gadolinium Deposits | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:34Z | 0 | 0 | 09000064b932a33a | |||
| FDA-2026-P-6737-0045 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 43 - An initial investigation of serum cytokine levels in patients with gadolinium retention | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:50Z | 0 | 0 | 09000064b932a33f | |||
| FDA-2026-P-6737-0030 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 28 - Skin-Related Adverse Reactions in Gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:56Z | 0 | 0 | 09000064b932a326 | |||
| FDA-2026-P-6737-0015 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 13 - Prepubertal exposure to gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:05Z | 0 | 0 | 09000064b932a309 | |||
| FDA-2026-P-6737-0018 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 16 - Immediate adverse reactions to gadolinium-based MR contrast | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:15Z | 0 | 0 | 09000064b932a30e | |||
| FDA-2026-P-6737-0037 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 35 - The Impact of Gadolinium on Quantitative Myelin Metrics | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:23Z | 0 | 0 | 09000064b932a337 | |||
| FDA-2026-P-6737-0005 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 3 - Gadolinium retention effect on macrophages | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:32Z | 0 | 0 | 09000064b932a275 | |||
| FDA-2026-P-6737-0021 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 19 - Gadolinium-based contrast agent toxicity | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:25Z | 0 | 0 | 09000064b932a311 | |||
| FDA-2026-P-6737-0024 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 22 - Gadolinium deposition in bone tissues after contrast-enhanced | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:37Z | 0 | 0 | 09000064b932a314 | |||
| FDA-2026-P-6737-0044 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 42 - Altered Functional Mitochondrial Protein Levels in Plasma | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:47Z | 0 | 0 | 09000064b932a33e | |||
| FDA-2026-P-6737-0041 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 39 - Delineating toxicity mechanisms associated with MRI contrast | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:37Z | 0 | 0 | 09000064b932a33b | |||
| FDA-2026-P-6737-0023 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 21 - Influence blocking by Gadolinium in Calcium Diffusion | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:33Z | 0 | 0 | 09000064b932a313 | |||
| FDA-2026-P-6737-0006 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 4 - Gadolinium accelerates the migration of astrocyte via integrin signaling pathway | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:36Z | 0 | 0 | 09000064b932a300 | |||
| FDA-2026-P-6737-0007 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:40Z | 0 | 0 | 09000064b932a301 | |||
| FDA-2026-P-6737-0010 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 8 - Repeated gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:50Z | 0 | 0 | 09000064b932a304 | |||
| FDA-2026-P-6737-0019 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 17 - Effects of Salicylate and Lanthanides on Outer Hair Cell Motility | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:19Z | 0 | 0 | 09000064b932a30f | |||
| FDA-2026-P-6737-0011 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 9 - Gadolinium Mitochondrial Toxicity | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:52Z | 0 | 0 | 09000064b932a305 | |||
| FDA-2026-P-6737-0017 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 15 - Gadolinium based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:11Z | 0 | 0 | 09000064b932a30d | |||
| FDA-2026-P-6737-0028 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 26 - Neurotoxicity from intrathecal gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:49Z | 0 | 0 | 09000064b932a324 | |||
| FDA-2026-P-6737-0031 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 29 - Acute lung injury following gadolinium contrast | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:00Z | 0 | 0 | 09000064b932a327 | |||
| FDA-2026-P-6737-0033 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 31 - Gadolinium-based contrast agent-induced neurotoxicity seeing is believing | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:07Z | 0 | 0 | 09000064b932a329 | |||
| FDA-2026-P-6737-0004 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 2 - Gadolinium-based MRI contrast agent effects on calcium signaling | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:30Z | 0 | 0 | 09000064b932a274 | |||
| FDA-2026-P-6737-0026 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 24 - Effects of Gadolinium-Based MRI Contrast | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:43Z | 0 | 0 | 09000064b932a322 | |||
| FDA-2026-P-6737-0014 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 12 - Skin-Related Adverse Reactions in Gadolinium-Based Contrast Agents-Induced Hypersensitivity | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:02Z | 0 | 0 | 09000064b932a308 | |||
| FDA-2026-P-6737-0022 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 20 - Human Hair as a Possible Surrogate Marker of Retained Tissue | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:30Z | 0 | 0 | 09000064b932a312 | |||
| FDA-2026-P-6737-0013 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 11 - On the interaction of muscle actin with gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:58Z | 0 | 0 | 09000064b932a307 | |||
| FDA-2026-P-6737-0016 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 14 - Contrast-free identification of glioma blood-brain barrier status via generative diffusion AI and non-contrast MRI | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:09Z | 0 | 0 | 09000064b932a30c | |||
| FDA-2026-P-6737-0036 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 34 - Immediate Adverse Reactions to Gandolinium-Based MR Contrast Media | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:20Z | 0 | 0 | 09000064b932a336 | |||
| FDA-2026-P-6737-0042 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 40 - The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:40Z | 0 | 0 | 09000064b932a33c | |||
| FDA-2026-P-6737-0001 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Citizen Petition from Regina Sutton | Other | Citizen Petition | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T20:27:13Z | 1 | 0 | 09000064b9329d15 | ||
| FDA-2026-P-6737-0002 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Acknowledgement Letter from FDA DMB to Regina Sutton | Other | Acknowledgement Letter/Receipt | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T20:27:18Z | 0 | 0 | 09000064b9329d18 | ||
| FDA-2026-P-6737-0025 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 23 - Assessment of gadolinium and iodine concentrations in kidney stones | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:40Z | 0 | 0 | 09000064b932a315 | |||
| FDA-2026-P-6737-0032 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 30 - Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:03Z | 0 | 0 | 09000064b932a328 | |||
| FDA-2026-P-6737-0027 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 25 - INDUCTION OF EXPRESSION OF PROFIBROTIC CYTOKINES | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:46Z | 0 | 0 | 09000064b932a323 | |||
| FDA-2026-P-6737-0020 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 18 - Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:22Z | 0 | 0 | 09000064b932a310 | |||
| FDA-2026-P-6737-0034 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 32 - Caught in the act Allergic-like reaction to | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:10Z | 0 | 0 | 09000064b932a32a | |||
| FDA-2026-P-6737-0038 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 36 - Effects of gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:26Z | 0 | 0 | 09000064b932a338 | |||
| FDA-2026-P-6737-0029 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 27 - Gadolinium during human pregnancy following administration of gadolinium chelate before pregnancy | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:52Z | 0 | 0 | 09000064b932a325 | |||
| FDA-2026-P-6737-0035 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 33 - Acute respiratory distress syndrome after the use of gadolinium contrast agent. | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:16Z | 0 | 0 | 09000064b932a32b | |||
| FDA-2026-P-6737-0039 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 37 - Gadolinium Contrast Agent Deposition in Children | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:30Z | 0 | 0 | 09000064b932a339 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;